[Clinical results and hormonal aspects of the treatment of virilizing symptoms in women with cyproterone acetate (author's transl)].
28 cases of moderate to severe hirsutism, two cases of acne and one case of axilary hidrosadenitis were tested continuously on average over 6 months by the daily administration of 100 mg cyproterone acetate. This drug was then given together with 1-2 mg oestradiol valerate over a further 6 month period by reversed sequential therapy. The effect of treatment was judged as being moderate only in 7 cases of idiopathic and one case of adrenal hirsutism and good in the remaining cases. However, this regimen caused a marked lowering of the urinary dehydroepiandrosterone sulphate and low polar oestrogen levels and also the plasma testosterone level. At the same time, according to preliminary results, the fraction of sex hormone binding globulin was raised. The plasma hydrocortisone level was depressed by about 20%. The fractions of 17-KS and 17-KGS decreased slightly at first, but then returned to normal. The side effects of continuous treatment were mainly gestagenic and of reversed sequential therapy mainly oestrogenic in nature. The continuation rate was 81% during a treatment period of two years.
D015068:17-Ketosteroids / Q000097:blood; D000152:Acne Vulgaris / Q000188:drug therapy; D000328:Adult; D003534:Cyproterone / Q000009:adverse effects / Q000627:therapeutic use*; D003687:Dehydroepiandrosterone / Q000652:urine; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000627:therapeutic use; D004967:Estrogens / Q000097:blood; D005260:Female; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008199:Lymphadenitis / Q000188:drug therapy; D008875:Middle Aged; D013739:Testosterone / Q000097:blood; D014770:Virilism / Q000188:drug therapy*
D015068:17-Ketosteroids; D004967:Estrogens; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D003534:Cyproterone; D006854:Hydrocortisone
Klinische Erfahrungen und hormonelle Aspekte bei der Behandlung von Virilisierungserscheinungen bei der Frau mit Cyproteronazetat.